Diabetes & Endocrinology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

This Phase 3 study is testing a once-weekly insulin called insulin icodec against the current daily insulin glargine regimen for adults with type 1 diabetes. If successful, insulin icodec could simplify the daily routine by reducing the number of injections patients need each week, potentially improving quality of life and treatment adherence. The study is recruiting participants worldwide, and results are expected in about eight and a half months.

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

This Phase 3 trial is evaluating the medication cagrilintide for people who have overweight or obesity. The goal is to see if cagrilintide helps reduce body weight safely and supports overall health improvements. Conducted in several countries including the United States, this study could lead to a new treatment choice for weight management after its expected 18-month duration.

Semaglutide in Treatment of Obesity

This completed Phase 3 trial studied semaglutide injections in adults with obesity in China. The results from 462 participants will help determine if semaglutide can be a safe and effective option for reducing body weight. Findings from this research may influence future treatments available for obesity around the world.

Diabetes Data-Assisted Remission Trial (DDART)

This study tested a high-intensity medical weight loss program combined with a digital support platform for adults living with type 2 diabetes and obesity. The approach aims to help patients lose weight and possibly achieve remission of diabetes through accessible digital tools. Conducted in the United States with 64 participants, the completed trial’s results are now available and may guide new diabetes management strategies.

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

This Phase 2 study is investigating the drug HM15275 for adults who are obese or overweight but do not have diabetes. The research looks to see if HM15275 can safely support weight loss and improve health outcomes. The trial lasts 36 weeks and is being conducted at multiple sites across the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.